Your SlideShare is downloading. ×
0
Data disclosure in Zambia
Data disclosure in Zambia
Data disclosure in Zambia
Data disclosure in Zambia
Data disclosure in Zambia
Data disclosure in Zambia
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Data disclosure in Zambia

980

Published on

Presentation by Owas Mwape, MeTA Zambia Council Member during the country sharing meeting, London 2009.

Presentation by Owas Mwape, MeTA Zambia Council Member during the country sharing meeting, London 2009.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
980
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Transcript

    • 1. Owas Mwape Council Member Data Disclosure in Zambia MeTA 18/01/10
    • 2. Type of data being collected
      • Policies, practices and results on
        • Registration
        • Availability
        • Pricing
        • Promotion
      18/01/10 MeTA
    • 3. Overview of disclosure process and engagement of stakeholders 
      • How is the data being disclosed?
      • Data is being disclosed through interviews with key informants in the pharmaceutical sector
      • Are the stakeholders involved? How?
      • The stakeholders are involved in the process both as data collectors and as key informants
      18/01/10 MeTA
    • 4. Challenges & lessons Learned
      • Brief overview of the main challenges
      • Bureaucracy
      • Unavailability of key informants
      • Unavailability of data (publications, etc)
      • General suspicion (why is this information being collected)
      • General lack of transparency in the medical field (confidentiality seems to apply in the sector)
      • Common view that the public lack interest in such matters and therefore there is no need for information to be in the public domain
      • What are the lessons learned so far?
      • There is need for increased lobbying for full data disclosure in pharmaceutical sector
      • Need for full commitment to MeTA principles from stakeholders
      • Bureaucracy is still a major challenge!!!!
      18/01/10 MeTA
    • 5. Type of support needed
      • Strategies for ensuring full commitment of all stakeholders to the MeTA principle of increased transparency
      • MeTA International to advise on how other countries have managed to link up to up to the national health reform process with health summits and joint evaluation
      18/01/10 MeTA
    • 6. Thank you!
      • Owas Mwape
      • oramwa@yahoo.com/
      • +260 955 857 161
      18/01/10 MeTA

    ×